Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanguard U.S. Momentum Factor ETF (NY:VFMO)

225.74 -2.95 (-1.29%)
Streaming Delayed Price Updated: 2:05 PM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanguard U.S. Momentum Factor ETF

< Previous 1 2 3 Next >
News headline image
Meet the Magnificent Momentum-Driven ETF Obliterating the S&P 500 in 2026 ↗
This actively managed exchange-traded fund is producing spectacular returns for investors thanks to its unique strategy. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
If You Invest $10,000 in the Vanguard U.S. Momentum Factor ETF (VFMO) Today, Here's What History Says You Could Have in 20 Years ↗
This relatively unknown ETF has outperformed the Russell 3000 and the S&P 500 over many periods. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
The Best ETF for the Investor Who Wants to Beat the Market While Barely Lifting a Finger ↗
You don't have to pick individual stocks to have a good shot at outperforming the market. 
Via The Motley Fool
Topics ETFs
Lyft Draws Investor Attention After Wedbush Downgrades Stock Amid Autonomous Vehicle Risks ↗
Via Stocktwits
American Eagle's Gen Z Playbook Is Working — Sydney Sweeney And Travis Kelce Might Only Be The Opening Act ↗
Via Stocktwits
News headline image
Meet the Magnificent Vanguard ETF Crushing the S&P 500 in 2026, Thanks to Its Unique Momentum-Driven Strategy ↗
This fund has just $2 billion in assets, but it might deserve more attention because of its solid returns. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
2 Vanguard Index Funds Are Crushing the S&P 500 This Year ↗
These Vanguard index funds have trounced the overall U.S. stock market this year. 
Via The Motley Fool
Topics ETFs Government Stocks
News headline image
2 Vanguard ETFs Beating the S&P 500 With a Momentum-Driven Strategy ↗
Vanguard's factor ETF lineup doesn't get a lot of attention. Its track record of market-beating returns suggests it should. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
3 Vanguard ETFs That Can Turn $1,000 per Month Into Over $1 Million ↗
Vanguard has exchange-traded funds that combine low fees with track records of attractive long-term returns. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
Meet the Magnificent Vanguard ETF Obliterating the S&P 500 in 2026 Because of Its Unique Momentum-Driven Strategy ↗
Most investors have probably never heard of this Vanguard ETF, but it routinely beats the market. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
This Vanguard ETF Has Outperformed the Company's S&P 500 Fund for Years. Most Investors Have Never Heard of It. ↗
Most people know Vanguard for its low-cost index funds. This smaller, actively managed ETF has been able to beat the S&P 500 for more than eight years. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
WIN Advisors Cuts Its FTC Stake by $10.6 Million -- Here's What Investors Should Know ↗
This fund tracks a rules-based index targeting U.S. large-cap growth stocks, using a systematic approach to portfolio construction. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
The Smartest Vanguard ETF to Buy With $1,000 Right Now ↗
This ETF is built to outperform in down markets. 
Via The Motley Fool
Topics ETFs
News headline image
Palladyne AI CEO Touts Expanded Backlog, Deeper Defense Engagement After Q4 Beat Sends PDYN Stock Soaring ↗
Palladyne AI reported a loss of $0.04 per share, down from a loss of $1.75 per share during the same quarter a year ago, and better than Wall Street’s expectations of a loss of $0.14 per share. 
Via Stocktwits
Topics Artificial Intelligence Stocks
News headline image
Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗
The biotech company reported statistically significant Phase 3 data for QTORIN gel. 
Via Stocktwits
News headline image
Why Did PDYN Stock Pop Over 10% In Pre-Market Today? ↗
The company signed an agreement with a major U.S. defense prime contractor to supply a subsystem that supports missile propulsion. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Cytokinetics Wins First FDA Approval For Heart Disease Drug — Why Is Wall Street Still Cautious? ↗
The FDA approved 5 mg, 10 mg, 15 mg, 20 mg Myqorzo tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. 
Via Stocktwits
News headline image
Why Is CorMedix Stock Rising Today? ↗
CorMedix said that its catheter lock solution showed fewer catheter-related bloodstream infections and secondary hospitalizations in adult dialysis patients in the interim study. 
Via Stocktwits
News headline image
Insmed Stock Plunges Nearly 20% After Hours As Sinus Drug Fails Mid-Stage Trial And Shows No Benefit ↗
While the drug was well tolerated with no new safety concerns, the drug yielded no positive treatment benefits in a study even at its highest dose of 40 mg. 
Via Stocktwits
News headline image
JPMorgan Investment Banking Chief Plans Exit After 45 Years As Bank Ramps Up AI And Braces For $105B Costs: Report ↗
According to Grant’s Linkedin profile, he joined the lender in 1980 as an investment banker after graduating from Oxford University and rose to be the global chairman of Investment banking. 
Via Stocktwits
Topics Artificial Intelligence Retirement
News headline image
Palantir CIO Jim Siders To Depart After 12 Years To Head Thrive Capital’s New IT Services Business ↗
im Siders said that Shield has an incredible combination of long-term vision, technological expertise, and operational know-how, making it perfect for him at the moment. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
ServiceNow Stock Is Down 5% Today — What’s Weighing On The Shares? ↗
KeyBank downgraded ServiceNow to ‘Underweight’ from ‘Sector Weight’ with a price target of $775. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Broadcom Stock Jumps After Hours As Strong Q4 And Surging AI Chip Demand Drive Upbeat Outlook ↗
The company now expects $19.1 billion in sales in the first quarter of fiscal year 2026, above an analyst estimate of $18.3 billion on the back of strong AI chip demand. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder ↗
The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management. 
Via Stocktwits
News headline image
Micron To Stop Selling Crucial Consumer Products As It Heightens Focus On Larger Customers ↗
The company said that it will continue to ship Crucial products to consumers through the end of February 2026. 
Via Stocktwits
News headline image
Abercrombie & Fitch Catches Retail Attention After Barclays Raises Price Target On Hollister Momentum ↗
Barclays raised its price target on Abercrombie & Fitch to $94 from $84 and maintained an ‘Equal Weight’ rating, according to TheFly. 
Via Stocktwits
News headline image
Why ANF Stock Is Soaring Before The Bell Today? ↗
Abercrombie now expects net sales to grow in the range of 6% to 7% for fiscal year 2025, compared with the prior forecast of 5% to 7% rise. 
Via Stocktwits
News headline image
Micron Stock Draws Investor Attention Following A Price Target Boost From UBS ↗
UBS maintained a ‘Buy’ rating on the shares and noted that its recent channel checks indicate "tight" supply conditions persist. 
Via Stocktwits
News headline image
AGIO Stock Cracks After Sickle-Cell Disease Drug Delivers Mixed Results In Late-Stage Trial ↗
While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance, Agios... 
Via Stocktwits
News headline image
OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results ↗
Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer. 
Via Stocktwits
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.